Fundraising Fox
BioCircuit Technologies
Atlanta, US · Founded 2016 · Georgia corporation · 46 employees on LinkedIn · 1 known investors
Find your way into BioCircuit Technologies
Sign up to see every warm intro you have to BioCircuit Technologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BioCircuit Technologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BioCircuit Technologies develops advanced medical devices for tissue repair and neuromodulation, with specialization in biomaterials, nitinol design, and bioelectronics. The company serves surgical teams with products like Nerve Tape®, a sutureless device for nerve repair.
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$13.7M disclosed across 3 rounds · 2019–2022
▶$9MraisedOct 2022 · 33 investors · BiotechnologyRule 506(b)
- Michelle JarrardExecutive Officer, Director
- James NahirnyDirector
- Michael MastersDirector
- Thomas O'BrienDirector
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Sep 2022
- Incorporated
- Corporation, Georgia
- Federal exemptions
- 04, 06b
▶$3.1MraisedApr 2021 · 13 investors · BiotechnologyRule 506(b)
- James NahirnyDirector
- Michael MastersDirector
- Thomas O'BrienDirector
- Michelle JarrardExecutive Officer, Director
- Offering amount
- $3.1M
- Amount sold
- $3.1M
- First sale
- Apr 2021
- Incorporated
- Corporation, Georgia, 2016
- Federal exemptions
- 04, 06b
▶$1.5MraisedApr 2021 · 7 investors · BiotechnologyRule 506(b)
- Michelle JarrardExecutive Officer, Director
- James NahirnyDirector
- Thomas O'BrienExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- May 2019
- Incorporated
- Corporation, Georgia, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as BioCircuit Technologies.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $1.9M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does BioCircuit Technologies do?
- BioCircuit Technologies develops advanced medical devices for tissue repair and neuromodulation, with specialization in biomaterials, nitinol design, and bioelectronics. The company serves surgical teams with products like Nerve Tape®, a sutureless device for nerve repair.
- Who are BioCircuit Technologies's investors?
- BioCircuit Technologies's investors include GRA Venture.
- How much funding has BioCircuit Technologies raised?
- BioCircuit Technologies has disclosed $13.7M raised across 3 rounds.
- Where is BioCircuit Technologies headquartered?
- BioCircuit Technologies is headquartered in Atlanta, US.